Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Fig. 4

Comprehensive AR-FL and AR-V distribution analysis in prostate cancer patient CTC samples. A A cohort of n = 422 PC CTC samples was analyzed for presence of CTCs (left circle). Subsequently, the CTC + cohort (n = 311) was dichotomously analyzed for expression of AR-FL and AR-Vs (middle circle). Finally, the CTC + /AR-FL + /AR-V + cohort (n = 205) was analyzed for expression of one AR-V, two AR-Vs and three AR-Vs (right circle). B Analysis of AR-FL transcript copy numbers in CTC + /AR-FL + samples (n = 289) separated by number of AR-Vs detected (** represent < 0.01, **** < 0.0001). C Correlation analysis of AR-FL transcript copy numbers (x-axis) and AR-V transcript copy numbers (y-axis)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us